PCIDB

KNApSAcK Metabolite C00018668

Metabolite

KNApSAcK Entry

id C00018668
Name MMC / Mitonco / Mitoplus / Mitocin C / Mutamycin / Ametycine / NSC 26980 / Mitomycin / Mitomycin C
CAS RN 50-07-7
Standard InChI InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
Standard InChI (Main Layer) InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)

Cluster

Phytochemical cluster
KCF-S cluster No. 3762

Link

ChEMBL

By standard InChI CHEMBL105
By standard InChI Main Layer CHEMBL105 CHEMBL518494 CHEMBL1354559 CHEMBL1518783

KEGG

By LinkDB C06681

CTD

By CAS RN D016685

Species

Summary

Plant class

class name count

Family

family name count
Streptomycetaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Streptomyces caespitosus 53502 Streptomycetaceae Bacteria

Human Protein / Gene in interaction

113 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL105 CHEMBL1909136 (2) CHEMBL2071965 (1)
1 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL1354559 CHEMBL1613992 (1)
7 / 44
Q16637 Survival motor neuron protein Unclassified protein CHEMBL1354559 CHEMBL1518783 CHEMBL1613842 (2)
4 / 2
Q99700 Ataxin-2 Unclassified protein CHEMBL518494 CHEMBL2114784 (1)
1 / 1
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL105 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL105 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL105 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL105 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL105 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL105 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL105 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL105 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL105 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL105 CHEMBL1909199 (2)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL105 CHEMBL1909197 (2)
2 / 2
P00918 Carbonic anhydrase 2 Lyase CHEMBL105 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL105 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL105 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL105 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL105 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL105 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909093 (2)
0 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL105 CHEMBL2075822 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL105 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL105 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL105 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL105 CHEMBL1909135 (2) CHEMBL2071963 (1)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL105 CHEMBL1909203 (2)
1 / 11
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL105 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL105 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL105 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL105 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL105 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL105 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL105 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL105 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL105 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL105 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL1518783 CHEMBL1614458 (1)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL105 CHEMBL1909133 (2)
0 / 0
P14902 Indoleamine 2,3-dioxygenase 1 Enzyme CHEMBL105 CHEMBL2346473 (1)
0 / 0
P42858 Huntingtin Unclassified protein CHEMBL1354559 CHEMBL1613918 (1)
1 / 1
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL518494 CHEMBL1794584 (1)
2 / 0
O75496 Geminin Unclassified protein CHEMBL105 CHEMBL518494 CHEMBL1354559 CHEMBL2114843 (1) CHEMBL2114780 (3)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL105 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL105 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL105 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL105 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL105 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL105 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL105 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL105 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL105 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL105 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL105 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL105 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL105 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL105 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL105 CHEMBL1909119 (2)
0 / 0
P63092 Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Other membrane protein CHEMBL518494 CHEMBL2114810 (1) CHEMBL2114817 (1)
7 / 3
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL1354559 CHEMBL1794467 (1)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL105 CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL105 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL105 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL105 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL105 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL105 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL105 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL105 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL105 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL105 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL105 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL105 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL105 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL105 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL105 CHEMBL1909132 (2) CHEMBL2071962 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL105 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL105 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL105 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL105 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL105 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL105 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL105 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL105 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL105 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL105 CHEMBL1909168 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL105 CHEMBL1909134 (2) CHEMBL2071964 (1)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL105 CHEMBL1354559 CHEMBL1614108 (1) CHEMBL1613886 (1)
CHEMBL1909138 (2) CHEMBL2071966 (1)
CHEMBL2071967 (1)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL105 CHEMBL1909137 (2)
0 / 0
Q9UNA4 DNA polymerase iota Enzyme CHEMBL105 CHEMBL1794483 (1)
0 / 0
P27695 DNA-(apurinic or apyrimidinic site) lyase Enzyme CHEMBL1354559 CHEMBL1518783 CHEMBL1614211 (2)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL1518783 CHEMBL1614250 (1) CHEMBL1614421 (1)
CHEMBL1614502 (1)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL105 CHEMBL518494 CHEMBL1738184 (2)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL105 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL105 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL105 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL105 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL105 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL105 CHEMBL1909128 (2)
0 / 0
Q9UBT6 DNA polymerase kappa Enzyme CHEMBL518494 CHEMBL1354559 CHEMBL1518783 CHEMBL1794536 (3)
0 / 0
B2RXH2 Lysine-specific demethylase 4E Enzyme CHEMBL1354559 CHEMBL1613914 (1)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL1354559 CHEMBL1518783 CHEMBL1614364 (2)
1 / 1
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic Enzyme CHEMBL518494 CHEMBL2354311 (1)
1 / 0
O00255 Menin Unclassified protein CHEMBL1354559 CHEMBL1614257 (1)
2 / 5
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL1354559 CHEMBL1614257 (1)
1 / 3
Q13951 Core-binding factor subunit beta Unclassified protein CHEMBL1518783 CHEMBL1613933 (1)
0 / 1
Q01196 Runt-related transcription factor 1 Unclassified protein CHEMBL1518783 CHEMBL1613933 (1)
1 / 6
P01215 Glycoprotein hormones alpha chain Unclassified protein CHEMBL518494 CHEMBL2114913 (1)
0 / 3

CTD interaction (358)

compound gene gene name gene description interaction interaction type form reference
pmid
D016685 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Mitomycin results in increased expression of ABCB1 protein increases expression
protein 17934748
D016685 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein results in decreased susceptibility to Mitomycin decreases response to substance
protein 11778547
D016685 3983 ABLIM1
ABLIM
LIMAB1
LIMATIN
abLIM-1
actin binding LIM protein 1 ABLIM1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 48 ACO1
ACONS
IREB1
IREBP
IREBP1
IRP1
aconitase 1, soluble (EC:4.2.1.3) ACO1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10965 ACOT2
CTE-IA
CTE1A
MTE1
PTE2
PTE2A
ZAP128
acyl-CoA thioesterase 2 (EC:3.1.2.2) ACOT2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2180 ACSL1
ACS1
FACL1
FACL2
LACS
LACS1
LACS2
acyl-CoA synthetase long-chain family member 1 (EC:6.2.1.3) ACSL1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2181 ACSL3
ACS3
FACL3
PRO2194
acyl-CoA synthetase long-chain family member 3 (EC:6.2.1.3) ACSL3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10768 AHCYL1
DCAL
IRBIT
PRO0233
XPVKONA
adenosylhomocysteinase-like 1 (EC:3.3.1.1) AHCYL1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9590 AKAP12
AKAP250
SSeCKS
A kinase (PRKA) anchor protein 12 AKAP12 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Mitomycin results in decreased expression of AKT1 protein modified form decreases expression
protein 16186332
D016685 214 ALCAM
CD166
MEMD
activated leukocyte cell adhesion molecule ALCAM protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 218 ALDH3A1
ALDH3
ALDHIII
aldehyde dehydrogenase 3 family, member A1 (EC:1.2.1.5) ALDH3A1 protein affects the susceptibility to Mitomycin affects response to substance
protein 15905174
D016685 316 AOX1
AO
AOH1
aldehyde oxidase 1 (EC:1.2.3.1) AOX1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 327 APEH
AARE
ACPH
APH
D3F15S2
D3S48E
DNF15S2
OPH
acylaminoacyl-peptide hydrolase (EC:3.4.19.1) APEH protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 328 APEX1
APE
APE1
APEN
APEX
APX
HAP1
REF1
APEX nuclease (multifunctional DNA repair enzyme) 1 (EC:4.2.99.18) APEX1 protein results in increased reduction of and results in increased susceptibility to Mitomycin increases reduction
/ increases response to substance
protein 10190555
D016685 27350 APOBEC3C
A3C
APOBEC1L
ARDC2
ARDC4
ARP5
PBI
bK150C2.3
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C APOBEC3C protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Mitomycin results in increased expression of APP mRNA increases expression
mRNA 12760830
D016685 427 ASAH1
AC
ACDase
ASAH
PHP
PHP32
SMAPME
N-acylsphingosine amidohydrolase (acid ceramidase) 1 (EC:3.5.1.23) ASAH1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 468 ATF4
CREB-2
CREB2
TAXREB67
TXREB
activating transcription factor 4 Mitomycin results in increased expression of ATF4 mRNA increases expression
mRNA 12760830
D016685 476 ATP1A1
ATPase, Na+/K+ transporting, alpha 1 polypeptide (EC:3.6.3.9) ATP1A1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 546 ATRX
ATR2
JMS
MRXHF1
RAD54
RAD54L
SFM1
SHS
XH2
XNP
ZNF-HX
alpha thalassemia/mental retardation syndrome X-linked (EC:3.6.4.12) ATRX protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 60370 AVPI1
PP5395
RP11-548K23.7
VIP32
VIT32
arginine vasopressin-induced 1 AVPI1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 25825 BACE2
AEPLC
ALP56
ASP1
ASP21
BAE2
CEAP1
DRAP
beta-site APP-cleaving enzyme 2 (EC:3.4.23.45) BACE2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 572 BAD
BBC2
BCL2L8
BCL2-associated agonist of cell death Mitomycin results in increased expression of BAD protein increases expression
protein 16186332
D016685 25805 BAMBI
NMA
BMP and activin membrane-bound inhibitor BAMBI protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 581 BAX
BCL2L4
BCL2-associated X protein Mitomycin affects the localization of BAX protein affects localization
protein 19834285
D016685 581 BAX
BCL2L4
BCL2-associated X protein Mitomycin results in decreased expression of BAX mRNA decreases expression
mRNA 19757172
D016685 581 BAX
BCL2L4
BCL2-associated X protein Mitomycin results in increased expression of BAX mRNA increases expression
mRNA 18615204
D016685 581 BAX
BCL2L4
BCL2-associated X protein Mitomycin results in increased expression of BAX protein increases expression
protein 11867586
15120327
D016685 581 BAX
BCL2L4
BCL2-associated X protein silybin inhibits the reaction [Mitomycin affects the localization of BAX protein] affects localization
/ decreases reaction
protein 19834285
D016685 581 BAX
BCL2L4
BCL2-associated X protein Tamoxifen promotes the reaction [Mitomycin results in decreased expression of BAX mRNA] decreases expression
/ increases reaction
mRNA 19757172
D016685 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Mitomycin affects the expression of BCL2 affects expression
19834285
D016685 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Mitomycin results in increased expression of BCL2 mRNA increases expression
mRNA 19757172
D016685 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Mitomycin results in increased expression of BCL2 protein increases expression
protein 11867586
15793875
D016685 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 silybin inhibits the reaction [Mitomycin affects the expression of BCL2] affects expression
/ decreases reaction
19834285
D016685 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Tamoxifen promotes the reaction [Mitomycin results in increased expression of BCL2 mRNA] increases expression
/ increases reaction
mRNA 19757172
D016685 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Mitomycin results in decreased expression of BCL2L1 mRNA decreases expression
mRNA 18615204
D016685 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Mitomycin results in increased expression of BCL2L1 protein increases expression
protein 11867586
D016685 55909 BIN3
bridging integrator 3 BIN3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 329 BIRC2
API1
HIAP2
Hiap-2
MIHB
RNF48
c-IAP1
cIAP1
baculoviral IAP repeat containing 2 BIRC2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 652 BMP4
BMP2B
BMP2B1
MCOPS6
OFC11
ZYME
bone morphogenetic protein 4 Mitomycin results in decreased expression of BMP4 mRNA decreases expression
mRNA 12760830
D016685 93664 CADPS2
Ca++-dependent secretion activator 2 CADPS2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) CDKN1A mutant form inhibits the reaction [Chloramphenicol inhibits the reaction [Mitomycin results in increased activity of CASP3 protein]] decreases reaction
/ increases activity
protein 15905168
D016685 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Chloramphenicol inhibits the reaction [Mitomycin results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 15905168
D016685 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Mitomycin co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 15120327
D016685 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Mitomycin promotes the reaction [CASP3 protein results in increased cleavage of PRKCD protein] increases cleavage
/ increases reaction
protein 10960761
D016685 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Mitomycin results in increased activity of CASP3 protein increases activity
protein 10960761
15905168
16186332
17094455
17530733
19834285
D016685 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Mitomycin results in increased cleavage of CASP3 protein increases cleavage
protein 16019139
17021654
D016685 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) Mitomycin results in increased cleavage of and results in increased activity of CASP7 protein increases activity
/ increases cleavage
protein 12181741
D016685 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Mitomycin results in increased activity of CASP8 protein increases activity
protein 10960761
17094455
17530733
D016685 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Mitomycin results in increased cleavage of and results in increased activity of CASP8 protein increases activity
/ increases cleavage
protein 12181741
D016685 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Mitomycin results in increased cleavage of CASP8 protein increases cleavage
protein 16019139
17021654
D016685 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Mitomycin promotes the reaction [CASP9 protein results in increased secretion of CYCS protein] increases reaction
/ increases secretion
protein 10960761
D016685 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Mitomycin results in increased activity of CASP9 protein increases activity
protein 16186332
17094455
17530733
D016685 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Mitomycin results in increased cleavage of and results in increased activity of CASP9 protein increases activity
/ increases cleavage
protein 12181741
D016685 56267 CCBL2
KAT3
KATIII
RP4-531M19.2
cysteine conjugate-beta lyase 2 (EC:2.6.1.7 4.4.1.13 2.6.1.63) CCBL2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Dexamethasone inhibits the reaction [Mitomycin results in increased expression of CCL2 mRNA] decreases reaction
/ increases expression
mRNA 20002897
D016685 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Dexamethasone inhibits the reaction [Mitomycin results in increased secretion of CCL2 protein] decreases reaction
/ increases secretion
protein 20002897
D016685 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Mitomycin results in increased expression of CCL2 mRNA increases expression
mRNA 20002897
D016685 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Mitomycin results in increased secretion of CCL2 protein increases secretion
protein 20002897
D016685 891 CCNB1
CCNB
cyclin B1 Mitomycin promotes the reaction [TP53 protein results in increased expression of CCNB1 mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 891 CCNB1
CCNB
cyclin B1 Mitomycin results in increased expression of CCNB1 mRNA increases expression
mRNA 12760830
18647660
D016685 966 CD59
16.3A5
1F5
EJ16
EJ30
EL32
G344
HRF-20
HRF20
MAC-IP
MACIF
MEM43
MIC11
MIN1
MIN2
MIN3
MIRL
MSK21
p18-20
CD59 molecule, complement regulatory protein Mitomycin results in increased mutagenesis of CD59 protein increases mutagenesis
protein 17045307
D016685 928 CD9
BTCC-1
DRAP-27
MIC3
MRP-1
TSPAN-29
TSPAN29
CD9 molecule CD9 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 978 CDA
CDD
cytidine deaminase (EC:3.5.4.5) CDA protein affects the susceptibility to [gemcitabine co-treated with Mitomycin] affects cotreatment
/ affects response to substance
protein 18728667
D016685 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) CDK2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A mutant form inhibits the reaction [Chloramphenicol inhibits the reaction [Mitomycin results in increased activity of CASP3 protein]] decreases reaction
/ increases activity
mutant form 15905168
D016685 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A mutant form inhibits the reaction [Chloramphenicol inhibits the reaction [Mitomycin results in increased activity of PARP1 protein]] decreases reaction
/ increases activity
mutant form 15905168
D016685 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Mitomycin promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Mitomycin results in increased expression of CDKN1A mRNA increases expression
mRNA 18647660
D016685 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Mitomycin results in increased stability of TP53 protein] which results in increased expression of CDKN1A mRNA increases expression
/ increases stability
mRNA 20536192
D016685 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B protein affects the susceptibility to Mitomycin affects response to substance
protein 17217824
D016685 9702 CEP57
MVA2
PIG8
TSP57
centrosomal protein 57kDa CEP57 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 26511 CHIC2
BTL
cysteine-rich hydrophobic domain 2 CHIC2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1159 CKMT1B
CKMT
CKMT1
UMTCK
creatine kinase, mitochondrial 1B (EC:2.7.3.2) CKMT1B protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1047 CLGN
calmegin CLGN protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1690 COCH
COCH-5B2
COCH5B2
DFNA9
DFNA31
cochlin COCH protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1284 COL4A2
ICH
POREN2
collagen, type IV, alpha 2 COL4A2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1299 COL9A3
DJ885L7.4.1
EDM3
IDD
MED
collagen, type IX, alpha 3 COL9A3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10063 COX17
COX17 cytochrome c oxidase copper chaperone COX17 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1373 CPS1
CPSASE1
PHN
carbamoyl-phosphate synthase 1, mitochondrial (EC:6.3.4.16) CPS1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10217 CTDSPL
C3orf8
HYA22
PSR1
RBSP3
SCP3
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like (EC:3.1.3.16) CTDSPL protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1495 CTNNA1
CAP102
catenin (cadherin-associated protein), alpha 1, 102kDa CTNNA1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6374 CXCL5
ENA-78
SCYB5
chemokine (C-X-C motif) ligand 5 CXCL5 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Mitomycin promotes the reaction [CASP9 protein results in increased secretion of CYCS protein] increases reaction
/ increases secretion
protein 10960761
D016685 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Mitomycin results in increased secretion of CYCS protein increases secretion
protein 10960761
16186332
D016685 64421 DCLRE1C
A-SCID
DCLREC1C
RS-SCID
SCIDA
SNM1C
hSNM1C
DNA cross-link repair 1C DCLRE1C results in decreased susceptibility to Mitomycin decreases response to substance
21785230
D016685 1638 DCT
TRP-2
TYRP2
dopachrome tautomerase (EC:5.3.3.12) DCT protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1643 DDB2
DDBB
UV-DDB2
damage-specific DNA binding protein 2, 48kDa Mitomycin promotes the reaction [TP53 protein results in increased expression of DDB2 mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 1643 DDB2
DDBB
UV-DDB2
damage-specific DNA binding protein 2, 48kDa Mitomycin results in increased expression of DDB2 mRNA increases expression
mRNA 18647660
D016685 54541 DDIT4
Dig2
REDD-1
REDD1
DNA-damage-inducible transcript 4 DDIT4 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 780 DDR1
CAK
CD167
DDR
EDDR1
HGK2
MCK10
NEP
NTRK4
PTK3
PTK3A
RTK6
TRKE
discoidin domain receptor tyrosine kinase 1 (EC:2.7.10.1) DDR1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 27122 DKK3
REIC
RIG
dickkopf WNT signaling pathway inhibitor 3 DKK3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1756 DMD
BMD
CMD3B
DXS142
DXS164
DXS206
DXS230
DXS239
DXS268
DXS269
DXS270
DXS272
dystrophin DMD protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10589 DRAP1
NC2-alpha
DR1-associated protein 1 (negative cofactor 2 alpha) DRAP1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 29940 DSE
DSEP
DSEPI
SART-2
SART2
dermatan sulfate epimerase (EC:5.1.3.19) DSE protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1846 DUSP4
HVH2
MKP-2
MKP2
TYP
dual specificity phosphatase 4 (EC:3.1.3.16 3.1.3.48) DUSP4 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1950 EGF
HOMG4
URG
epidermal growth factor Mitomycin inhibits the reaction [EGF protein results in increased uptake of Zinc] decreases reaction
/ increases uptake
protein 1502195
D016685 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 EGR1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 Mitomycin results in increased expression of EGR1 mRNA increases expression
mRNA 12760830
D016685 9669 EIF5B
IF2
eukaryotic translation initiation factor 5B EIF5B protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2004 ELK3
ERP
NET
SAP2
ELK3, ETS-domain protein (SRF accessory protein 2) ELK3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2013 EMP2
XMP
epithelial membrane protein 2 EMP2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1969 EPHA2
ARCC2
CTPA
CTPP1
CTRCT6
ECK
EPH receptor A2 (EC:2.7.10.1) Mitomycin results in decreased expression of EPHA2 mRNA decreases expression
mRNA 12760830
D016685 2065 ERBB3
ErbB-3
HER3
LCCS2
MDA-BF-1
c-erbB-3
c-erbB3
erbB3-S
p180-ErbB3
p45-sErbB3
p85-sErbB3
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (EC:2.7.10.1) ERBB3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 405754 ERVFRD-1
ERVFRDE1
GLLL6191
HERV-FRD
HERV-W/FRD
UNQ6191
envFRD
endogenous retrovirus group FRD, member 1 ERVFRD-1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2149 F2R
CF2R
HTR
PAR-1
PAR1
TR
coagulation factor II (thrombin) receptor F2R protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 116496 FAM129A
C1orf24
NIBAN
family with sequence similarity 129, member A FAM129A protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 221061 FAM171A1
C10orf38
family with sequence similarity 171, member A1 FAM171A1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 55603 FAM46A
C6orf37
XTP11
family with sequence similarity 46, member A FAM46A protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 22909 FAN1
KIAA1018
KMIN
MTMR15
FANCD2/FANCI-associated nuclease 1 (EC:3.1.4.1) FAN1 gene mutant form results in increased susceptibility to Mitomycin increases response to substance
gene 22772369
D016685 22909 FAN1
KIAA1018
KMIN
MTMR15
FANCD2/FANCI-associated nuclease 1 (EC:3.1.4.1) FAN1 protein results in decreased susceptibility to Mitomycin decreases response to substance
protein 21115814
D016685 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Mitomycin affects the splicing of FAS gene affects splicing
gene 18571879
D016685 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Mitomycin results in increased expression of and results in increased secretion of FAS protein alternative form increases expression
/ increases secretion
protein 18571879
D016685 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Mitomycin results in increased expression of FAS mRNA increases expression
mRNA 16957513
D016685 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Mitomycin results in increased expression of FAS protein increases expression
protein 11867586
16186332
16957513
D016685 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Mitomycin results in increased expression of FASLG increases expression
16019139
D016685 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Mitomycin results in increased expression of FASLG mRNA increases expression
mRNA 16957513
D016685 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Mitomycin results in increased expression of FASLG protein increases expression
protein 16186332
16957513
D016685 2195 FAT1
CDHF7
CDHR8
FAT
ME5
hFat1
FAT atypical cadherin 1 FAT1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2091 FBL
FIB
FLRN
RNU3IP1
fibrillarin Mitomycin analog affects the localization of FBL protein affects localization
protein 10942594
D016685 2222 FDFT1
DGPT
ERG9
SQS
SS
farnesyl-diphosphate farnesyltransferase 1 (EC:2.5.1.21) FDFT1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2247 FGF2
BFGF
FGF-2
FGFB
HBGF-2
fibroblast growth factor 2 (basic) Mitomycin results in increased expression of FGF2 protein increases expression
protein 16585851
D016685 2273 FHL1
FHL-1
FHL1A
FHL1B
FLH1A
KYOT
SLIM
SLIM-1
SLIM1
SLIMMER
XMPMA
four and a half LIM domains 1 FHL1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 51024 FIS1
TTC11
fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) FIS1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog FOS protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2534 FYN
SLK
SYN
p59-FYN
FYN oncogene related to SRC, FGR, YES (EC:2.7.10.2) FYN protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 50486 G0S2
RP1-28O10.2
G0/G1switch 2 G0S2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha Mitomycin promotes the reaction [TP53 protein results in increased expression of GADD45A mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha Mitomycin results in increased expression of GADD45A mRNA increases expression
mRNA 18647660
D016685 2579 GAGE7
AL4
CT4.7
GAGE-7
G antigen 7 GAGE7 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9289 GPR56
BFPP
TM7LN4
TM7XN1
G protein-coupled receptor 56 GPR56 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 29899 GPSM2
CMCS
DFNB82
LGN
PINS
G-protein signaling modulator 2 GPSM2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2948 GSTM4
GSTM4-4
GTM4
glutathione S-transferase mu 4 (EC:2.5.1.18) GSTM4 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 mRNA results in increased susceptibility to Mitomycin increases response to substance
mRNA 15239142
D016685 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Mitomycin results in increased phosphorylation of H2AFX protein increases phosphorylation
protein 21386838
D016685 3059 HCLS1
CTTNL
HS1
hematopoietic cell-specific Lyn substrate 1 HCLS1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9734 HDAC9
HD7
HD7b
HD9
HDAC
HDAC7
HDAC7B
HDAC9B
HDAC9FL
HDRP
MITR
histone deacetylase 9 (EC:3.5.1.98) HDAC9 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 23462 HEY1
BHLHb31
CHF2
HERP2
HESR1
HRT-1
OAF1
hHRT1
hes-related family bHLH transcription factor with YRPW motif 1 HEY1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3087 HHEX
HEX
HMPH
HOX11L-PEN
PRH
PRHX
hematopoietically expressed homeobox HHEX protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3107 HLA-C
D6S204
HLA-JY3
HLC-C
PSORS1
major histocompatibility complex, class I, C Mitomycin results in decreased expression of HLA-C mRNA decreases expression
mRNA 12760830
D016685 10362 HMG20B
BRAF25
BRAF35
HMGX2
HMGXB2
PP7706
SMARCE1r
SOXL
pp8857
high mobility group 20B HMG20B protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3159 HMGA1
HMG-R
HMGA1A
HMGIY
high mobility group AT-hook 1 HMGA1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 8091 HMGA2
BABL
HMGI-C
HMGIC
LIPO
STQTL9
high mobility group AT-hook 2 HMGA2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3312 HSPA8
HSC54
HSC70
HSC71
HSP71
HSP73
HSPA10
LAP1
NIP71
heat shock 70kDa protein 8 Mitomycin promotes the reaction [TP53 protein results in increased expression of HSPA8 mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 3312 HSPA8
HSC54
HSC70
HSC71
HSP71
HSP73
HSPA10
LAP1
NIP71
heat shock 70kDa protein 8 Mitomycin results in increased expression of HSPA8 mRNA increases expression
mRNA 18647660
D016685 23463 ICMT
HSTE14
MST098
MSTP098
PCCMT
PCMT
PPMT
isoprenylcysteine carboxyl methyltransferase (EC:2.1.1.100) ICMT protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3400 ID4
IDB4
bHLHb27
inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3606 IL18
IGIF
IL-18
IL-1g
IL1F4
interleukin 18 (interferon-gamma-inducing factor) Mitomycin results in decreased expression of IL18 decreases expression
17021654
D016685 3606 IL18
IGIF
IL-18
IL-1g
IL1F4
interleukin 18 (interferon-gamma-inducing factor) Mitomycin results in decreased expression of IL18 protein decreases expression
protein 16019139
D016685 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta IL1B protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Mitomycin affects the reaction [IL1B protein results in increased uptake of Zinc] affects reaction
/ increases uptake
protein 1502195
D016685 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Dexamethasone inhibits the reaction [Mitomycin results in increased expression of IL8 mRNA] decreases reaction
/ increases expression
mRNA 20002897
D016685 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Dexamethasone inhibits the reaction [Mitomycin results in increased secretion of IL8 protein] decreases reaction
/ increases secretion
protein 20002897
D016685 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Mitomycin results in increased expression of IL8 mRNA increases expression
mRNA 20002897
D016685 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Mitomycin results in increased secretion of IL8 protein increases secretion
protein 20002897
D016685 3613 IMPA2
inositol(myo)-1(or 4)-monophosphatase 2 (EC:3.1.3.25) IMPA2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 221037 JMJD1C
RP11-10C13.2
TRIP8
jumonji domain containing 1C JMJD1C protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 23189 KANK1
ANKRD15
CPSQ2
KANK
KN motif and ankyrin repeat domains 1 KANK1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 23254 KAZN
KAZ
kazrin, periplakin interacting protein KAZN protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9493 KIF23
CHO1
KNSL5
MKLP-1
MKLP1
kinesin family member 23 KIF23 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3897 L1CAM
CAML1
CD171
HSAS
HSAS1
MASA
MIC5
N-CAM-L1
N-CAML1
NCAM-L1
S10
SPG1
L1 cell adhesion molecule L1CAM protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3958 LGALS3
CBP35
GAL3
GALBP
GALIG
L31
LGALS2
MAC2
lectin, galactoside-binding, soluble, 3 LGALS3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 3978 LIG1
ligase I, DNA, ATP-dependent (EC:6.5.1.1) Mitomycin results in decreased expression of LIG1 mRNA decreases expression
mRNA 12760830
D016685 22998 LIMCH1
LIMCH1A
LMO7B
LIM and calponin homology domains 1 LIMCH1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9516 LITAF
PIG7
SIMPLE
TP53I7
lipopolysaccharide-induced TNF factor LITAF protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4000 LMNA
CDCD1
CDDC
CMD1A
CMT2B1
EMD2
FPL
FPLD
FPLD2
HGPS
IDC
LDP1
LFP
LGMD1B
LMN1
LMNC
LMNL1
PRO1
lamin A/C LMNA protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4053 LTBP2
C14orf141
GLC3D
LTBP3
MSPKA
MSTP031
WMS3
latent transforming growth factor beta binding protein 2 LTBP2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4111 MAGEA12
CT1.12
MAGE12
melanoma antigen family A, 12 MAGEA12 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4111 MAGEA12
CT1.12
MAGE12
melanoma antigen family A, 12 [[MIR34A binds to MAGEA12 3' UTR] which results in decreased expression of MAGEA12 protein] which results in increased susceptibility to Mitomycin affects binding
/ decreases expression
/ increases response to substance
3' UTR / protein 21177782
D016685 4102 MAGEA3
CT1.3
HIP8
HYPD
MAGE3
MAGEA6
melanoma antigen family A, 3 [[MIR34A binds to MAGEA3 3' UTR] which results in decreased expression of MAGEA3 protein] which results in increased susceptibility to Mitomycin affects binding
/ decreases expression
/ increases response to substance
3' UTR / protein 21177782
D016685 4105 MAGEA6
CT1.6
MAGE-3b
MAGE3B
MAGE6
melanoma antigen family A, 6 MAGEA6 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4105 MAGEA6
CT1.6
MAGE-3b
MAGE3B
MAGE6
melanoma antigen family A, 6 [[MIR34A binds to MAGEA6 3' UTR] which results in decreased expression of MAGEA6 protein] which results in increased susceptibility to Mitomycin affects binding
/ decreases expression
/ increases response to substance
3' UTR / protein 21177782
D016685 4116 MAGOH
MAGOH1
MAGOHA
mago-nashi homolog, proliferation-associated (Drosophila) MAGOH protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
protein 21810436
D016685 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) MAP2K1 results in decreased susceptibility to [Curcumin co-treated with Mitomycin] affects cotreatment
/ decreases response to substance
21810436
D016685 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
protein 21810436
D016685 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) MAP2K2 results in decreased susceptibility to [Curcumin co-treated with Mitomycin] affects cotreatment
/ decreases response to substance
21810436
D016685 9053 MAP7
E-MAP-115
EMAP115
microtubule-associated protein 7 MAP7 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Mitomycin results in increased phosphorylation of MAPK1 protein increases phosphorylation
protein 21810436
D016685 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) U 0126 promotes the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]] decreases reaction
/ increases phosphorylation
/ increases reaction
protein 21810436
D016685 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) Dexamethasone inhibits the reaction [Mitomycin results in increased activity of and results in increased phosphorylation of MAPK14 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 20002897
D016685 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) Mitomycin results in increased activity of and results in increased phosphorylation of MAPK14 protein increases activity
/ increases phosphorylation
protein 20002897
D016685 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]] decreases reaction
/ increases phosphorylation
protein 21810436
D016685 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Mitomycin results in increased phosphorylation of MAPK3 protein increases phosphorylation
protein 21810436
D016685 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) U 0126 promotes the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]] decreases reaction
/ increases phosphorylation
/ increases reaction
protein 21810436
D016685 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) Mitomycin results in increased activity of and results in increased phosphorylation of MAPK8 protein increases activity
/ increases phosphorylation
protein 16186332
D016685 22919 MAPRE1
EB1
microtubule-associated protein, RP/EB family, member 1 Mitomycin results in increased expression of MAPRE1 mRNA increases expression
mRNA 12760830
D016685 4147 MATN2
matrilin 2 MATN2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4155 MBP
myelin basic protein MBP protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4192 MDK
ARAP
MK
NEGF2
midkine (neurite growth-promoting factor 2) MDK protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase Mitomycin results in increased expression of MDM2 protein increases expression
protein 18096571
D016685 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase [Mitomycin results in increased stability of TP53 protein] which results in increased expression of MDM2 mRNA increases expression
/ increases stability
mRNA 20536192
D016685 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) Buthionine Sulfoximine inhibits the reaction [MGMT protein results in increased susceptibility to Mitomycin] decreases reaction
/ increases response to substance
protein 16039682
D016685 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) Glutathione affects the reaction [MGMT protein results in increased susceptibility to Mitomycin] affects reaction
/ increases response to substance
protein 16039682
D016685 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) MGMT protein results in increased susceptibility to Mitomycin increases response to substance
protein 16039682
D016685 407040 MIR34A
MIRN34A
miRNA34A
mir-34
microRNA 34a [[MIR34A binds to MAGEA12 3' UTR] which results in decreased expression of MAGEA12 protein] which results in increased susceptibility to Mitomycin affects binding
/ decreases expression
/ increases response to substance
21177782
D016685 407040 MIR34A
MIRN34A
miRNA34A
mir-34
microRNA 34a [[MIR34A binds to MAGEA3 3' UTR] which results in decreased expression of MAGEA3 protein] which results in increased susceptibility to Mitomycin affects binding
/ decreases expression
/ increases response to substance
21177782
D016685 407040 MIR34A
MIRN34A
miRNA34A
mir-34
microRNA 34a [[MIR34A binds to MAGEA6 3' UTR] which results in decreased expression of MAGEA6 protein] which results in increased susceptibility to Mitomycin affects binding
/ decreases expression
/ increases response to substance
21177782
D016685 4311 MME
CALLA
CD10
NEP
SFE
membrane metallo-endopeptidase (EC:3.4.24.11) MME protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4323 MMP14
MMP-14
MMP-X1
MT-MMP
MT-MMP_1
MT1-MMP
MT1MMP
MTMMP1
WNCHRS
matrix metallopeptidase 14 (membrane-inserted) (EC:3.4.24.80) Mitomycin results in decreased expression of MMP14 mRNA decreases expression
mRNA 12760830
D016685 5891 MOK
RAGE
RAGE-1
RAGE1
MOK protein kinase (EC:2.7.11.22) MOK protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4493 MT1E
MT1
MTD
metallothionein 1E MT1E protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4599 MX1
IFI-78K
IFI78
MX
MxA
myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) MX1 protein results in increased susceptibility to Mitomycin increases response to substance
protein 9389754
D016685 29116 MYLIP
IDOL
MIR
myosin regulatory light chain interacting protein (EC:6.3.2.-) MYLIP protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4651 MYO10
myosin X MYO10 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4739 NEDD9
CAS-L
CAS2
CASL
CASS2
HEF1
neural precursor cell expressed, developmentally down-regulated 9 NEDD9 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 4800 NFYA
CBF-A
CBF-B
HAP2
NF-YA
nuclear transcription factor Y, alpha Mitomycin results in increased expression of NFYA mRNA increases expression
mRNA 12760830
D016685 4800 NFYA
CBF-A
CBF-B
HAP2
NF-YA
nuclear transcription factor Y, alpha NFYA protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9397 NMT2
N-myristoyltransferase 2 (EC:2.3.1.97) NMT2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) [arsenite results in increased expression of NQO1 protein] which results in increased susceptibility to Mitomycin increases expression
/ increases response to substance
protein 16494910
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) Dicumarol inhibits the reaction [[arsenite results in increased expression of NQO1 protein] which results in increased susceptibility to Mitomycin] decreases reaction
/ increases expression
/ increases response to substance
protein 16494910
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) Dicumarol inhibits the reaction [NQO1 protein results in increased metabolism of Mitomycin] decreases reaction
/ increases metabolic processing
protein 1701346
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) [Dicumarol results in decreased activity of NQO1 protein] which results in decreased susceptibility to Mitomycin decreases activity
/ decreases response to substance
protein 15655414
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) [dimethyl fumarate results in increased activity of NQO1 protein] which results in increased susceptibility to Mitomycin increases activity
/ increases response to substance
protein 15655414
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) NQO1 mRNA results in increased susceptibility to Mitomycin increases response to substance
mRNA 15239142
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) NQO1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) NQO1 protein results in increased metabolism of and results in increased susceptibility to Mitomycin increases metabolic processing
/ increases response to substance
protein 9865924
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) NQO1 protein results in increased metabolism of Mitomycin increases metabolic processing
protein 1701346
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) NQO1 protein results in increased susceptibility to Mitomycin increases response to substance
protein 16494910
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) [Oxygen deficiency co-treated with Mitomycin] results in decreased activity of NQO1 protein affects cotreatment
/ decreases activity
protein 16226770
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) [Tetrachlorodibenzodioxin co-treated with Mitomycin co-treated with Oxygen deficiency] affects the activity of NQO1 protein affects activity
/ affects cotreatment
protein 16226770
D016685 1728 NQO1
DHQU
DIA4
DTD
NMOR1
NMORI
QR1
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) [Tetrachlorodibenzodioxin co-treated with Mitomycin] results in decreased activity of NQO1 protein affects cotreatment
/ decreases activity
protein 16226770
D016685 8204 NRIP1
RIP140
nuclear receptor interacting protein 1 NRIP1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) CDKN1A mutant form inhibits the reaction [Chloramphenicol inhibits the reaction [Mitomycin results in increased activity of PARP1 protein]] decreases reaction
/ increases activity
protein 15905168
D016685 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Chloramphenicol inhibits the reaction [Mitomycin results in increased activity of PARP1 protein] decreases reaction
/ increases activity
protein 15905168
D016685 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Mitomycin results in increased activity of PARP1 protein increases activity
protein 15905168
D016685 55872 PBK
CT84
Nori-3
SPK
TOPK
PDZ binding kinase (EC:2.7.12.2) PBK protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5111 PCNA
proliferating cell nuclear antigen Mitomycin promotes the reaction [TP53 protein results in increased expression of PCNA mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 5111 PCNA
proliferating cell nuclear antigen Mitomycin results in increased expression of PCNA mRNA increases expression
mRNA 18647660
D016685 23244 PDS5A
SCC-112
SCC112
PDS5, regulator of cohesion maintenance, homolog A (S. cerevisiae) PDS5A protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 8566 PDXK
C21orf124
C21orf97
PKH
PNK
pyridoxal (pyridoxine, vitamin B6) kinase (EC:2.7.1.35) PDXK protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 8544 PIR
pirin (iron-binding nuclear protein) (EC:1.13.11.24) PIR protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5569 PKIA
PRKACN1
protein kinase (cAMP-dependent, catalytic) inhibitor alpha PKIA protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5328 PLAU
ATF
BDPLT5
QPD
UPA
URK
u-PA
plasminogen activator, urokinase (EC:3.4.21.73) PLAU protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5354 PLP1
GPM6C
HLD1
MMPL
PLP
PLP/DM20
PMD
SPG2
proteolipid protein 1 PLP1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6490 PMEL
D12S53E
ME20
ME20-M
ME20M
P1
P100
PMEL17
SI
SIL
SILV
gp100
premelanosome protein PMEL protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5376 PMP22
CMT1A
CMT1E
DSS
GAS-3
HMSNIA
HNPP
Sp110
peripheral myelin protein 22 PMP22 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5447 POR
CPR
CYPOR
P450R
P450 (cytochrome) oxidoreductase (EC:1.6.2.4) POR mRNA results in increased susceptibility to Mitomycin increases response to substance
mRNA 15239142
D016685 5447 POR
CPR
CYPOR
P450R
P450 (cytochrome) oxidoreductase (EC:1.6.2.4) POR protein results in increased susceptibility to Mitomycin increases response to substance
protein 21386838
D016685 5580 PRKCD
MAY1
PKCD
nPKC-delta
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) Mitomycin promotes the reaction [CASP3 protein results in increased cleavage of PRKCD protein] increases cleavage
/ increases reaction
protein 10960761
D016685 5590 PRKCZ
PKC-ZETA
PKC2
protein kinase C, zeta (EC:2.7.11.13) Mitomycin results in increased cleavage of PRKCZ protein increases cleavage
protein 10960761
D016685 5621 PRNP
ASCR
AltPrP
CD230
CJD
GSS
KURU
PRIP
PrP
PrP27-30
PrP33-35C
PrPc
p27-30
prion protein Mitomycin results in increased expression of PRNP mRNA increases expression
mRNA 12760830
D016685 23215 PRRC2C
BAT2-iso
BAT2D1
BAT2L2
XTP2
proline-rich coiled-coil 2C PRRC2C protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Mitomycin results in increased expression of PTGS2 protein increases expression
protein 15793875
D016685 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Sulindac inhibits the reaction [Mitomycin results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 15793875
D016685 64284 RAB17
RAB17, member RAS oncogene family RAB17 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 55647 RAB20
RAB20, member RAS oncogene family RAB20 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase acetylleucyl-leucyl-norleucinal inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase acetylleucyl-leucyl-norleucinal inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein] decreases reaction
/ increases expression
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase [Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA affects cotreatment
/ decreases expression
mRNA 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase Mitomycin results in increased expression of RAD51 protein increases expression
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase RAD51 results in decreased susceptibility to [Curcumin co-treated with Mitomycin] affects cotreatment
/ decreases response to substance
21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase U 0126 promotes the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 21810436
D016685 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase U 0126 promotes the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA] affects cotreatment
/ decreases expression
/ increases reaction
mRNA 21810436
D016685 5889 RAD51C
BROVCA3
FANCO
R51H3
RAD51L2
RAD51 paralog C RAD51C gene mutant form results in increased susceptibility to Mitomycin increases response to substance
gene 20400963
D016685 11186 RASSF1
123F2
NORE2A
RASSF1A
RDA32
REH3P21
Ras association (RalGDS/AF-6) domain family member 1 RASSF1 protein results in increased susceptibility to Mitomycin increases response to substance
protein 17444856
D016685 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Mitomycin results in decreased expression of RB1 protein modified form decreases expression
protein 15617745
D016685 5931 RBBP7
RbAp46
retinoblastoma binding protein 7 Mitomycin results in increased expression of RBBP7 mRNA increases expression
mRNA 12760830
D016685 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Mitomycin results in increased expression of RELA increases expression
16019139
17021654
D016685 5983 RFC3
RFC38
replication factor C (activator 1) 3, 38kDa RFC3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5984 RFC4
A1
RFC37
replication factor C (activator 1) 4, 37kDa Mitomycin results in decreased expression of RFC4 mRNA decreases expression
mRNA 12760830
D016685 6189 RPS3A
FTE1
MFTL
S3A
ribosomal protein S3A Mitomycin results in increased expression of RPS3A mRNA increases expression
mRNA 12760830
D016685 864 RUNX3
AML2
CBFA3
PEBP2aC
runt-related transcription factor 3 RUNX3 protein results in increased susceptibility to Mitomycin increases response to substance
protein 15756676
D016685 6281 S100A10
42C
ANX2L
ANX2LG
CAL1L
CLP11
Ca[1]
GP11
P11
p10
S100 calcium binding protein A10 S100A10 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6282 S100A11
MLN70
S100C
S100 calcium binding protein A11 S100A11 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6275 S100A4
18A2
42A
CAPL
FSP1
MTS1
P9KA
PEL98
S100 calcium binding protein A4 S100A4 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6303 SAT1
DC21
KFSD
KFSDX
SAT
SSAT
SSAT-1
spermidine/spermine N1-acetyltransferase 1 (EC:2.3.1.57) SAT1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6447 SCG5
7B2
P7B2
SGNE1
SgV
secretogranin V (7B2 protein) SCG5 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5055 SERPINB2
HsT1201
PAI
PAI-2
PAI2
PLANH2
serpin peptidase inhibitor, clade B (ovalbumin), member 2 SERPINB2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 SERPINE1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6446 SGK1
SGK
serum/glucocorticoid regulated kinase 1 (EC:2.7.11.1) Mitomycin promotes the reaction [TP53 protein results in increased expression of SGK1 mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 6446 SGK1
SGK
serum/glucocorticoid regulated kinase 1 (EC:2.7.11.1) Mitomycin results in increased expression of SGK1 mRNA increases expression
mRNA 18647660
D016685 9467 SH3BP5
SAB
SH3BP-5
SH3-domain binding protein 5 (BTK-associated) SH3BP5 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9120 SLC16A6
MCT6
MCT7
solute carrier family 16, member 6 SLC16A6 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6505 SLC1A1
EAAC1
EAAT3
SCZD18
solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 SLC1A1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 11000 SLC27A3
ACSVL3
FATP3
VLCS-3
solute carrier family 27 (fatty acid transporter), member 3 (EC:6.2.1.-) SLC27A3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10924 SMPDL3A
ASM3A
ASML3a
yR36GH4.1
sphingomyelin phosphodiesterase, acid-like 3A SMPDL3A protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6647 SOD1
ALS
ALS1
IPOA
SOD
hSod1
homodimer
superoxide dismutase 1, soluble (EC:1.15.1.1) Mitomycin results in increased expression of SOD1 mRNA increases expression
mRNA 18647660
D016685 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10580 SORBS1
CAP
FLAF2
R85FL
SH3D5
SH3P12
SORB1
sorbin and SH3 domain containing 1 SORBS1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6272 SORT1
Gp95
LDLCQ6
NT3
sortilin 1 SORT1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 5552 SRGN
PPG
PRG
PRG1
serglycin SRGN protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 6426 SRSF1
ASF
SF2
SF2p33
SFRS1
SRp30a
serine/arginine-rich splicing factor 1 SRSF1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7982 ST7
ETS7q
FAM4A
FAM4A1
HELG
RAY1
SEN4
TSG7
suppression of tumorigenicity 7 ST7 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 8614 STC2
STC-2
STCRP
stanniocalcin 2 STC2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 10923 SUB1
P15
PC4
p14
SUB1 homolog (S. cerevisiae) Mitomycin results in increased expression of SUB1 mRNA increases expression
mRNA 12760830
D016685 55638 SYBU
GOLSYN
OCSYN
SNPHL
syntabulin (syntaxin-interacting) SYBU protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 81550 TDRD3
tudor domain containing 3 TDRD3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7020 TFAP2A
AP-2
AP-2alpha
AP2TF
BOFS
TFAP2
transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) TFAP2A protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7033 TFF3
ITF
P1B
TFI
trefoil factor 3 (intestinal) TFF3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7035 TFPI
EPI
LACI
TFI
TFPI1
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) TFPI protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7980 TFPI2
PP5
REF1
TFPI-2
tissue factor pathway inhibitor 2 TFPI2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 23483 TGDS
SDR2E1
TDPGD
TDP-glucose 4,6-dehydratase (EC:4.2.1.46) TGDS protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Mitomycin results in increased expression of TGFB1 protein increases expression
protein 16585851
D016685 7045 TGFBI
BIGH3
CDB1
CDG2
CDGG1
CSD
CSD1
CSD2
CSD3
EBMD
LCD1
transforming growth factor, beta-induced, 68kDa Mitomycin results in decreased expression of TGFBI mRNA decreases expression
mRNA 18615204
D016685 7045 TGFBI
BIGH3
CDB1
CDG2
CDGG1
CSD
CSD1
CSD2
CSD3
EBMD
LCD1
transforming growth factor, beta-induced, 68kDa Mitomycin results in decreased expression of TGFBI protein decreases expression
protein 18615204
D016685 7052 TGM2
G-ALPHA-h
GNAH
TG2
TGC
transglutaminase 2 (EC:2.3.2.13) TGM2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 80008 TMEM156
transmembrane protein 156 TMEM156 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 27346 TMEM97
MAC30
transmembrane protein 97 TMEM97 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Mitomycin co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 15120327
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of CCNB1 mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of DDB2 mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of GADD45A mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of HSPA8 mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of PCNA mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of SGK1 mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of TP53I3 mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin promotes the reaction [TP53 protein results in increased expression of TRIAP1 mRNA] increases expression
/ increases reaction
protein 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin results in increased expression of TP53 increases expression
19834285
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin results in increased expression of TP53 mRNA increases expression
mRNA 18647660
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin results in increased expression of TP53 protein increases expression
protein 12082016
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin results in increased expression of TP53 protein modified form increases expression
protein 16186332
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Mitomycin results in increased stability of TP53 protein increases stability
protein 20536192
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Mitomycin results in increased stability of TP53 protein] which results in increased expression of CDKN1A mRNA increases expression
/ increases stability
protein 20536192
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Mitomycin results in increased stability of TP53 protein] which results in increased expression of MDM2 mRNA increases expression
/ increases stability
protein 20536192
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 silybin inhibits the reaction [Mitomycin results in increased expression of TP53] decreases reaction
/ increases expression
19834285
D016685 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 protein affects the susceptibility to Mitomycin affects response to substance
protein 15182437
20000476
D016685 9540 TP53I3
PIG3
tumor protein p53 inducible protein 3 Mitomycin promotes the reaction [TP53 protein results in increased expression of TP53I3 mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 9540 TP53I3
PIG3
tumor protein p53 inducible protein 3 Mitomycin results in increased expression of TP53I3 mRNA increases expression
mRNA 18647660
D016685 7163 TPD52
D52
N8L
PC-1
PrLZ
hD52
tumor protein D52 TPD52 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 51499 TRIAP1
MDM35
P53CSV
WF-1
TP53 regulated inhibitor of apoptosis 1 Mitomycin promotes the reaction [TP53 protein results in increased expression of TRIAP1 mRNA] increases expression
/ increases reaction
mRNA 18647660
D016685 51499 TRIAP1
MDM35
P53CSV
WF-1
TP53 regulated inhibitor of apoptosis 1 Mitomycin results in increased expression of TRIAP1 mRNA increases expression
mRNA 18647660
D016685 28951 TRIB2
C5FW
GS3955
TRB2
tribbles pseudokinase 2 TRIB2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 23321 TRIM2
CMT2R
RNF86
tripartite motif containing 2 TRIM2 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 22059 TRP53 protein affects the reaction [Mitomycin results in increased expression of TRP73 protein] affects reaction
/ increases expression
protein 17530733
D016685 22062 Mitomycin results in increased expression of TRP73 protein increases expression
protein 17530733
D016685 22062 TRP53 protein affects the reaction [Mitomycin results in increased expression of TRP73 protein] affects reaction
/ increases expression
protein 17530733
D016685 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) Mitomycin results in decreased expression of TYMP mRNA decreases expression
mRNA 16568373
D016685 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP protein affects the susceptibility to [gemcitabine co-treated with Mitomycin] affects cotreatment
/ affects response to substance
protein 18728667
D016685 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Mitomycin results in increased expression of TYMS mRNA increases expression
mRNA 16568373
D016685 5412 UBL3
HCG-1
PNSC1
ubiquitin-like 3 UBL3 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7345 UCHL1
NDGOA
PARK5
PGP_9.5
PGP9.5
PGP95
Uch-L1
ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) (EC:3.4.19.12) UCHL1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7372 UMPS
OPRT
uridine monophosphate synthetase (EC:2.4.2.10 4.1.1.23) Mitomycin results in decreased expression of UMPS mRNA decreases expression
mRNA 16568373
D016685 55062 WIPI1
ATG18
ATG18A
WIPI49
WD repeat domain, phosphoinositide interacting 1 WIPI1 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7474 WNT5A
hWNT5A
wingless-type MMTV integration site family, member 5A WNT5A protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 9589 WTAP
Wilms tumor 1 associated protein WTAP protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747
D016685 7498 XDH
XO
XOR
xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) Mitomycin results in decreased activity of XDH protein decreases activity
protein 16226770
D016685 7498 XDH
XO
XOR
xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) [Oxygen deficiency co-treated with Mitomycin] results in decreased activity of XDH protein affects cotreatment
/ decreases activity
protein 16226770
D016685 7498 XDH
XO
XOR
xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) [Tetrachlorodibenzodioxin co-treated with Mitomycin co-treated with Oxygen deficiency] affects the activity of XDH protein affects activity
/ affects cotreatment
protein 16226770
D016685 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis XIAP protein affects the susceptibility to Mitomycin affects response to substance
protein 17641843
D016685 7518 XRCC4
X-ray repair complementing defective repair in Chinese hamster cells 4 XRCC4 results in decreased susceptibility to Mitomycin decreases response to substance
21785230
D016685 23528 ZNF281
ZBP-99
ZNP-99
zinc finger protein 281 ZNF281 protein affects the susceptibility to Mitomycin affects response to substance
protein 16217747

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (67)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#219080 Acth-independent macronodular adrenal hyperplasia; aimah P63092
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#300615 Brunner syndrome P21397
#114500 Colorectal cancer; crc P84022
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#600274 Frontotemporal dementia; ftd P10636
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 O75874
P04626
#605130 Hairy elbows, short stature, facial dysmorphism, and developmental delay Q03164
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#143100 Huntington disease; hd P42858
#145000 Hyperparathyroidism 1; hrpt1 O00255
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#608516 Major depressive disorder; mdd P08172
#174800 Mccune-albright syndrome; mas P63092
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#131100 Multiple endocrine neoplasia, type i; men1 O00255
#126200 Multiple sclerosis, susceptibility to; ms P08575
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#166350 Osseous heteroplasia, progressive; poh P63092
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260500 Papilloma of choroid plexus; cpp P04637
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#172700 Pick disease of brain P10636
#102200 Pituitary adenoma, growth hormone-secreting P63092
#601399 Platelet disorder, familial, with associated myeloid malignancy Q01196
#103580 Pseudohypoparathyroidism, type ia; php1a P63092
#603233 Pseudohypoparathyroidism, type ib; php1b P63092
#612462 Pseudohypoparathyroidism, type ic; php1c P63092
#607276 Resting heart rate, variation in P08588
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#607250 Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 Q9NUW8
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#190300 Tremor, hereditary essential, 1; etm1 P35462
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (74)

KEGG disease name UniProt
H00033 Adrenal carcinoma O00255 (related)
P04637 (related)
H00034 Carcinoid O00255 (related)
H00045 Malignant islet cell carcinoma O00255 (related)
H00246 Primary hyperparathyroidism O00255 (related)
H01102 Pituitary adenomas O00255 (related)
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00081 Hashimoto's thyroiditis P01215 (marker)
H00082 Graves' disease P01215 (marker)
H00250 Congenital nongoitrous hypothyroidism (CHNG) P01215 (marker)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
Q01196 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00059 Huntington's disease (HD) P42858 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00244 Pseudohypoparathyroidism P63092 (related)
H00441 Progressive osseous heteroplasia (POH) P63092 (related)
H00501 Fibrous dysplasia, polyostotic P63092 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Q01196 (related)
Q01196 (marker)
Q03164 (related)
Q03164 (marker)
H00003 Acute myeloid leukemia (AML) Q01196 (related)
Q01196 (marker)
Q13951 (marker)
H00978 Thrombocytopenia (THC) Q01196 (related)
H00002 Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Q03164 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)
Q9NUW8 (related)

Diseases related to CTD interactions

127 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D058186 D016685 Acute Kidney Injury marker/mechanism
2508290
2982552
6796250
6870446
D000230 D016685 Adenocarcinoma therapeutic
2112726
3093413
6340628
12166705
C538231 D016685 Adenocarcinoma of lung therapeutic
15384034
D000740 D016685 Anemia marker/mechanism
1609513
6340628
9660540
15724837
18000507
D000741 D016685 Anemia, Aplastic marker/mechanism
6010939
D000743 D016685 Anemia, Hemolytic marker/mechanism
1782316
3093413
3150472
6105503
6406059
6796250
7379025
D001002 D016685 Anuria marker/mechanism
12813674
D001005 D016685 Anus Neoplasms therapeutic
1782316
1906166
10761566
18591164
D001167 D016685 Arteritis marker/mechanism
9087350
D001259 D016685 Ataxia marker/mechanism
15793395
D001284 D016685 Atrophy marker/mechanism
6796250
D053099 D016685 Azotemia marker/mechanism
9152802
D001649 D016685 Bile Duct Diseases marker/mechanism
12720104
D001855 D016685 Bone Marrow Diseases marker/mechanism
2982552
D001943 D016685 Breast Neoplasms therapeutic
1906166
2829807
3932789
6810311
7491579
8483557
9004059
D002114 D016685 Calcinosis marker/mechanism
1454338
1807206
8256682
D002277 D016685 Carcinoma therapeutic
2934584
7491579
D002289 D016685 Carcinoma, Non-Small-Cell Lung therapeutic
1339077
2982552
8043059
8209274
8635092
8635384
10574676
10928138
21277290
D002294 D016685 Carcinoma, Squamous Cell therapeutic
1782316
7379025
8901858
9774881
18591164
D002295 D016685 Carcinoma, Transitional Cell therapeutic
10071561
10368221
10691844
12579346
18814818
D016893 D016685 Carotid Stenosis marker/mechanism
9087350
D002386 D016685 Cataract marker/mechanism
1454338
D002637 D016685 Chest Pain marker/mechanism
11734065
D002764 D016685 Cholecystitis marker/mechanism
6225318
D002921 D016685 Cicatrix therapeutic
16113371
D003110 D016685 Colonic Neoplasms therapeutic
2112726
3093413
12166705
D015179 D016685 Colorectal Neoplasms therapeutic
1906166
2934584
9660540
12813674
17187072
D003231 D016685 Conjunctivitis marker/mechanism
9759389
D003316 D016685 Corneal Diseases therapeutic
20002897
C535474 D016685 Corneal dystrophy Avellino type therapeutic
18615204
D015715 D016685 Corneal Edema marker/mechanism
1454338
D003318 D016685 Corneal Opacity therapeutic
16805119
D057112 D016685 Corneal Perforation marker/mechanism
1454338
D017577 D016685 Cutaneous Fistula marker/mechanism
18814818
D003556 D016685 Cystitis marker/mechanism
1796854
2127988
3929577
3931326
8256682
10691844
11912421
19829042
D003711 D016685 Demyelinating Diseases marker/mechanism
2129960
D003967 D016685 Diarrhea marker/mechanism
9660540
12119460
18000507
D018450 D016685 Disease Progression therapeutic
9660540
D004342 D016685 Drug Hypersensitivity marker/mechanism
2127988
D064420 D016685 Drug-Related Side Effects and Adverse Reactions marker/mechanism
1458553
3101142
15793395
D004427 D016685 Ear Diseases marker/mechanism
15793395
D004487 D016685 Edema marker/mechanism
9152802
D004802 D016685 Eosinophilia marker/mechanism
1796854
2127988
11912421
D004890 D016685 Erythema marker/mechanism
2996749
D004938 D016685 Esophageal Neoplasms therapeutic
1519930
C562729 D016685 Esophageal Squamous Cell Carcinoma therapeutic
8543635
D005119 D016685 Extravasation of Diagnostic and Therapeutic Materials marker/mechanism
1906166
3129617
18814818
D005221 D016685 Fatigue marker/mechanism
1519930
D005334 D016685 Fever marker/mechanism
9660540
D005355 D016685 Fibrosis marker/mechanism
2508290
6796250
D005770 D016685 Gastrointestinal Neoplasms therapeutic
6796250
8712831
18000507
D005901 D016685 Glaucoma marker/mechanism
1454338
D005902 D016685 Glaucoma, Open-Angle therapeutic
7825687
D005909 D016685 Glioblastoma therapeutic
15655414
D006258 D016685 Head and Neck Neoplasms therapeutic
8901858
9774881
D006333 D016685 Heart Failure marker/mechanism
688243
3101142
3137399
3932789
D006417 D016685 Hematuria therapeutic
2996749
D006461 D016685 Hemolysis marker/mechanism
6104085
D006463 D016685 Hemolytic-Uremic Syndrome marker/mechanism
1519930
2104558
2112726
2114657
2493141
2658095
2934584
3085480
3101142
3108839
3142062
3876775
3927871
6210069
6313552
6401771
6437662
6870446
7491579
7679450
7917560
8061399
8215482
8222875
8483557
8712831
9016902
9152802
9660541
10178695
10761566
10892085
11219485
11604563
12053072
12119460
12166705
12421219
12588957
12813674
15340761
15384034
16388419
18591164
D006470 D016685 Hemorrhage marker/mechanism
3927871
8222875
12813674
D006504 D016685 Hepatic Veno-Occlusive Disease marker/mechanism
2829807
D006869 D016685 Hydronephrosis therapeutic
2996749
D006932 D016685 Hyperbilirubinemia marker/mechanism
1519930
D006947 D016685 Hyperkalemia marker/mechanism
9152802
D006973 D016685 Hypertension marker/mechanism
9152802
D006994 D016685 Hypoaldosteronism marker/mechanism
8061399
D007008 D016685 Hypokalemia marker/mechanism
1339077
D007010 D016685 Hyponatremia marker/mechanism
1339077
D045823 D016685 Ileus marker/mechanism
10928138
D007238 D016685 Infarction marker/mechanism
3876775
D007412 D016685 Intestinal Fistula marker/mechanism
18814818
D007499 D016685 Iris Diseases marker/mechanism
1454338
D007500 D016685 Iritis marker/mechanism
9759389
D007673 D016685 Kidney Cortex Necrosis marker/mechanism
6796250
D007674 D016685 Kidney Diseases marker/mechanism
6010939
6105503
D007676 D016685 Kidney Failure, Chronic marker/mechanism
6340628
6796250
6810311
9016902
D007970 D016685 Leukopenia marker/mechanism
9660540
10928138
12119460
18000507
D008113 D016685 Liver Neoplasms therapeutic
1908657
2506836
2934584
2943876
7944421
9087350
15113037
D008171 D016685 Lung Diseases marker/mechanism
2982552
3101142
3927871
8222875
D008175 D016685 Lung Neoplasms therapeutic
1906166
D052016 D016685 Mucositis marker/mechanism
9660540
18000507
D009102 D016685 Multiple Organ Failure marker/mechanism
9016902
D009325 D016685 Nausea marker/mechanism
2982552
10928138
18000507
18591164
D009336 D016685 Necrosis marker/mechanism
1906166
3129617
3876775
6790156
19829042
D009362 D016685 Neoplasm Metastasis therapeutic
2506836
2934584
2943876
12720104
D009369 D016685 Neoplasms therapeutic
16019139
D009422 D016685 Nervous System Diseases marker/mechanism
1260786
D020258 D016685 Neurotoxicity Syndromes marker/mechanism
2982552
D009503 D016685 Neutropenia marker/mechanism
15724837
D015814 D016685 Ocular Hypotension marker/mechanism
7825687
8336889
8357056
9031300
9076802
9859998
D009846 D016685 Oliguria marker/mechanism
6437662
D010051 D016685 Ovarian Neoplasms therapeutic
21852251
D010146 D016685 Pain marker/mechanism
1454338
3129617
9759389
D010167 D016685 Pallor marker/mechanism
9152802
D010190 D016685 Pancreatic Neoplasms therapeutic
1906166
6796250
15113037
18000507
D017699 D016685 Pelvic Pain therapeutic
2996749
D020795 D016685 Photophobia marker/mechanism
1454338
9759389
D011183 D016685 Postoperative Complications marker/mechanism
therapeutic
16113371
19829042
D011471 D016685 Prostatic Neoplasms therapeutic
6340628
D011625 D016685 Pterygium therapeutic
9759389
D011654 D016685 Pulmonary Edema marker/mechanism
3093413
6406059
12813674
D011668 D016685 Pulmonary Veno-Occlusive Disease marker/mechanism
11955658
D011681 D016685 Pupil Disorders marker/mechanism
1454338
D011697 D016685 Purpura, Thrombotic Thrombocytopenic marker/mechanism
11604563
16388419
D012004 D016685 Rectal Neoplasms therapeutic
2112726
D012008 D016685 Recurrence therapeutic
9660540
9759389
D051437 D016685 Renal Insufficiency marker/mechanism
1339077
1609513
2493141
3093413
3108839
3150472
6104085
6210069
6232549
6406059
6437662
7379025
9660541
10071561
12053072
12813674
12873041
D015356 D016685 Retinal Artery Occlusion marker/mechanism
7852024
D012170 D016685 Retinal Vein Occlusion marker/mechanism
7852024
D015422 D016685 Scleral Diseases marker/mechanism
1454338
D012871 D016685 Skin Diseases marker/mechanism
6420039
12119460
18000507
D012883 D016685 Skin Ulcer marker/mechanism
1906166
D013274 D016685 Stomach Neoplasms therapeutic
1519930
1906166
1908657
6401771
6437662
7944421
8061399
8215482
9152802
12119460
D013280 D016685 Stomatitis marker/mechanism
12119460
18000507
D013921 D016685 Thrombocytopenia marker/mechanism
6796250
9660540
12119460
15724837
18000507
D013927 D016685 Thrombosis marker/mechanism
6810311
9087350
D014517 D016685 Ureteral Obstruction marker/mechanism
10071561
10368221
12566821
D001745 D016685 Urinary Bladder Diseases marker/mechanism
1807206
2508290
D001747 D016685 Urinary Bladder Fistula marker/mechanism
18814818
D001749 D016685 Urinary Bladder Neoplasms therapeutic
1807206
3929577
3931326
6420039
7581512
7729958
9052763
9089042
9252197
10071561
10368221
11912421
12478111
12566821
12579346
14678389
18814818
19829042
D014555 D016685 Urination Disorders marker/mechanism
7581512
8230546
D014652 D016685 Vascular Diseases marker/mechanism
6796250
9016902
D019043 D016685 Vascular Neoplasms marker/mechanism
3927871
D014719 D016685 Vesicovaginal Fistula marker/mechanism
18814818
D014786 D016685 Vision Disorders marker/mechanism
8336889
9076802
9859998
D014839 D016685 Vomiting marker/mechanism
2982552
8635092
10928138
12119460
18000507
D014947 D016685 Wounds and Injuries therapeutic
20002897